NasdaqGS:INBXBiotechs
Inhibrx Biosciences (INBX) Earnings Put Its Valuation Back In Focus
Inhibrx Biosciences (INBX) is back in focus after reporting second quarter 2026 results, with a quarterly net loss of US$36.65 million and a six month net loss of US$70.09 million.
See our latest analysis for Inhibrx Biosciences.
Despite the wider loss this quarter, Inhibrx Biosciences shares have climbed strongly over 2026, with a year to date share price return of 32.13% and a very large 1 year total shareholder return of 296.60%. Recent trading has been choppy, with the share price down...